BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTX · IEX Real-Time Price · USD
6.23
+0.62 (11.05%)
At close: Jun 24, 2022 4:00 PM
6.09
-0.14 (-2.25%)
After-hours: Jun 24, 2022 7:50 PM EDT
11.05%
Market Cap 96.68M
Revenue (ttm) n/a
Net Income (ttm) -14.34M
Shares Out 15.52M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,158,650
Open 5.67
Previous Close 5.61
Day's Range 5.67 - 6.38
52-Week Range 4.06 - 12.47
Beta 1.65
Analysts Buy
Price Target 11.86 (+90.4%)
Earnings Date Jul 5, 2022

About BCTX

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is h... [Read more...]

Industry Biotechnology
Founded 2014
Employees 5
Stock Exchange NASDAQ
Ticker Symbol BCTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BCTX stock is "Buy." The 12-month stock price forecast is 11.86, which is an increase of 90.37% from the latest price.

Price Target
$11.86
(90.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

Creatv Bio's LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 3...

ROCKVILLE, Md.--(BUSINESS WIRE)--Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response of...

BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology ...

Why Is BriaCell (BCTX) Stock Moving Today?

BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?

Why BriaCell Therapeutics Stock Is Surging Today

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of...

BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...

BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Researc...

PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...

BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

PHILADELPHIA and VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...

BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that all re...

BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on N...

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechno...

BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®

NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology co...

BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study

NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology co...

BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechn...

Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop

Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.

Other symbols: ASLEBGFVSAVA

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when...

Other symbols: SAVAASLEBGFV

BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scien...

NEW YORK and VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology co...

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology co...

BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favo...

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotec...

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotec...

BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceuti...

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body...

BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies

Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization. In the U.S., 12.9% of ...